Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Shanghai Pulse Medical Technology / Equity Capital Markets

Shanghai Pulse Medical Technology (PMT HK)

<ul>
<li>Shanghai Pulse is a leading player in the FFR assessment in China. The company is looking to raise up to USD 200 m via a Hong Kong listing.</li>
<li>We look at the company's key products QFR, OFR and UFR. We also provide our thoughts on the investment thesis.</li>
<li>We think the company has a decent investor backing and meanwhile we also highlight concerns on its management.</li>
</ul>


Shanghai Pulse is a leading player in the FFR assessment in China. The company is looking to raise up to USD 200 m via a Hong Kong listing.
We look at the company's key products QFR, OFR and UFR. We also provide our thoughts on the investment thesis.
We think the company has a decent investor backing and meanwhile we also highlight concerns on its management.


Shanghai Pulse Medical (博动医疗) Pre-IPO: Leading Image-Based FFR Player